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Abstract 
Complement factor H is a major regulator of the alternative pathway of the complement system. 
The factor H-related proteins are less characterized, but recent data indicate that they rather 
promote complement activation. These proteins have some common ligands with factor H and 
have both overlapping and distinct functions depending on domain composition and the degree of 
conservation of amino acid sequence. Factor H and some of the factor H-related proteins also 
appear in a non-canonical function that is beyond their role in the modulation of complement 
activation. This review covers our current understanding on this emerging role of factor H family 
proteins in modulating the activation and function of various cells by binding to receptors or 
receptor ligands. 
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1. Introduction 
The complement system is an essential humoral arm of innate immunity, with versatile functions 
involved in maintaining host homeostasis [1, 2]. Complement has a major role in the recognition 
of microbes and defence against pathogens, which is based on its ability to discriminate self from 
non-self, and promote opsonophagocytosis and lysis of microbes. Complement also participates 
in the disposal of immune complexes, dying cells and cell debris, in the regulation of 
inflammation and activation of various cells. The complement system consists of more than 40 
soluble and cell membrane-bound proteins. Complement can be activated through three major 
pathways in a cascade-like manner [1]. The classical pathway is activated when C1q in the C1 
complex binds to selected microbes and host ligands, such as antigen-bound immunoglobulins 
and pentraxins, and to apoptotic/necrotic cells. The lectin pathway is activated upon the 
interaction of mannan-binding lectin or ficolins with specific carbohydrates. The alternative 
pathway is activated constitutively at a low rate by the spontaneous hydrolysis of C3, which is the 
central molecule of complement. In addition, all activation pathways, via the generation of C3b 
from C3, feed into the alternative pathway, which then serves as an amplification mechanism of 
complement activation (Fig. 1). The effector mechanisms of complement are mediated by the 
direct lytic effect of the common terminal pathway, and by cellular receptors that bind the various 
activation fragments generated from the complement components during propagation of the 
activation cascades. Fragments of the central C3 molecule bind to complement receptors type 1 
(CR1, binds C3b), type 2 (CR2, binds C3d), types 3 and 4 (CR3 and CR4, bind iC3b), and to the 
anaphylatoxin receptor C3aR (binds the C3a fragment) [3]. CR3 and CR4 serve as major opsonin 
receptors on myeloid cells, and have several additional ligands (discussed in more detail in 
section 3.1). CR2 is part of the B-cell receptor co-receptor complex and its engagement with C3d 
lowers the threshold for B cell activation. 
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Regulatory molecules in body fluids and on cell surfaces keep complement activation in 
check, which otherwise could lead to inflammation and tissue damage. Uncontrolled or 
misdirected complement activation is implicated in a growing number of diseases, both systemic 
and organ-specific ones [4, 5]. Dysregulation of the alternative pathway in particular is associated 
with diseases such as atypical hemolytic uremic syndrome, C3 glomerulopathy and age-related 
macular degeneration (AMD) [5-8]. The major soluble inhibitor of the alternative pathway is 
complement factor H (Fig.1) [9]. 
 
2. The role of the complement factor H family proteins in the modulation of complement 
activation 
2.1. Factor H as a complement regulator 
Factor H is a 155-kDa glycoprotein that consists of 20 complement control protein (CCP) 
domains, from which the four N-terminal domains provide the complement inhibitory functions 
of factor H. This activity is realized both in fluid phase and on host cellular and non-cellular 
surfaces, thus factor H supports the protection of host cells which are in contact with complement 
(e.g., platelets, erythrocytes, leukocytes and endothelial cells)  [10, 11]. To perform this latter 
function, factor H has to properly discriminate self surfaces from non-self surfaces, which ability 
highly depends on the most C-terminal part (CCP19-20) of the molecule [12-17]. These domains 
include binding sites for C3b/C3d that is deposited on a surface, as well as for polyanionic host 
markers, such as glycosaminoglycans (GAGs) and sialic acid [12, 18-20]. The dual recognition of 
C3b and GAGs/sialic acid allows docking of factor H on the host surface in a conformation that 
favours its complement regulatory activity (mediated by the N-terminal domains). CCP7 harbors 
an additional binding site for negatively charged host markers [21]. These and other domains also 
mediate important interactions with ligands such as pentraxins, extracellular matrix (ECM) 
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proteins, malondialdehyde adducts and DNA (Fig. 2) (reviewed in [11, 22]). Interaction of factor 
H with these ligands is thought to direct the complement inhibitory activity of factor H to sites of 
ongoing complement activation and inflammation (Fig. 3A) [10, 11, 23]. Factor H 
polymorphisms, mutations and autoantibodies that influence factor H levels or interaction with 
certain ligands, or affect its function, were described in association with several diseases [24-27]. 
 Factor H-like protein 1 (FHL-1), a splice variant derived from the CFH gene, includes the 
CCPs 1-7 of factor H plus four amino acids at its C-terminal end. Thus, FHL-1 can also bind C3b 
and inhibit complement activation [28]. While this protein has not been extensively investigated, 
it might be more important than previously appreciated, because recent evidence suggests that at 
specific anatomic sites, such as the Bruch’s membrane in the eye, FHL-1 may pass this barrier 
whereas factor H, due to its large size, cannot pass [29]. The CCP7 and CCPs 19-20 domains 
contain recognition sites for different GAGs, which can target FHL-1 and factor H to different 
sites; FHL-1 also lacks the sialic acid-binding site present in CCP20 [18, 29]. 
 
2.2. The factor H-related (FHR) proteins as positive modulators of complement activation 
Factor H is a member of a protein family that also includes FHL-1, as well as five factor H-
related proteins (FHRs) that are derived from five highly related genes [30]. FHRs are also 
composed exclusively of CCPs of varying numbers, and show immunological cross-reactivity 
with each other and with factor H. Each FHR has domains homologous to the CCP19-20 domains 
of factor H, and some domains homologous to factor H domains CCPs 6-9 (also CCPs 10-14 in 
FHR-5), but lacks the N-terminal complement regulatory domains (Fig. 2).  
The FHRs may share binding ability to some of the factor H ligands due to these 
homologies [30]. However, in spite of the relatedness between the respective domains, the FHRs 
may do not, or with markedly different avidity, bind to certain factor H ligands. For example, 
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while both factor H and FHR-4 bind to C-reactive protein (CRP), factor H binds predominantly 
the modified monomeric CRP form, whereas FHR-4 binds the native pentameric CRP form [31-
33]. FHR-5 binds pentraxin 3 (PTX3) stronger, and FHR-1 binds PTX3 weaker than factor H, 
and FHR-4 does not show significant PTX3 binding [34-36]. These ligand binding profiles 
influence the function of the proteins. FHR-4 can activate the classical pathway via recruited 
CRP [37]. FHR-5 can inhibit factor H binding to pentraxins and ECM and thus indirectly 
promote complement activation [34]. FHR-1, FHR-4 and FHR-5 can bind C3b via their C-
terminal domains and allow for the formation of the C3bBb alternative pathway C3 convertase 
and thus activate the alternative pathway, an activity similar to that previously described for 
properdin (Fig. 3A) [34, 38, 39]. In addition, CCPs 1-2 of FHR-1, FHR-2 and FHR-5 mediate 
dimerization of the proteins, which increases the avidity of these FHRs to e.g. surface-bound 
C3b, resulting in more efficient competition with factor H [40-42]. 
Indeed, the FHR proteins recently emerged as positive complement regulators, in contrast 
with the inhibiting role of factor H [30]. For several of them the ability to competitively inhibit 
factor H binding to certain host ligands has been demonstrated. This includes surface-bound C3b, 
ECM and the pentraxins CRP and PTX3 [34, 38, 40-43]. In addition, FHR-3 was shown to 
compete with factor H for a bacterial ligand, namely, to inhibit factor H binding to the fHbp 
protein of Neisseria meningitidis [43].  
This gene cluster evolved through segmental duplications, which due to the homologies 
make this cluster prone to gene rearrangements. These give rise to gene deletions and 
duplications, as well as partial gene deletions and duplications leading to the formation of hybrid 
genes, and thus abnormal hybrid proteins. By removing or introducing FHRs as competitors of 
factor H, by altering their oligomeric structure or exchanging their recognition domains, these 
changes alter the balance between complement activation and inhibition, and are associated with 
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a number of human disorders, e.g. the kidney diseases atypical hemolytic uremic syndrome, C3 
glomerulopathy (including CFHR5 nephropathy), IgA nephropathy; systemic lupus 
erythematosus; and also AMD, by conferring susceptibility or protection (reviewed in [30, 44]). 
For example, the lack of FHR-1 and FHR-3 due to the prevalent CFHR3-CFHR1 gene deletion is 
strongly associated with lower risk of developing IgA nephropathy [45] and AMD [46], likely 
due to the less amount of FHRs to interfere with the complement regulatory activity of factor H 
[30]. It was very recently shown indeed, that FHR-1 serum levels and the FHR-1:factor H ratio 
are higher in IgA nephropathy patients compared with healthy controls [47, 48]. Factor H 
pathogenic variants causing decreased factor H activity and certain haplotypes that determine 
different factor H and FHR-1/FHR-3 serum levels modulate the FH/FHR balance and influence 
susceptibility to diseases [48-52]. 
 
3. Factor H family proteins in their non-canonical role as modulators of cellular functions 
In addition to their role in modulating complement activation, factor H family proteins were 
shown to bind to receptors and modulate cell functions / cellular activation (summarized in Table 
1 and Fig. 3B). In the next sections, this non-canonical role of factor H and the FHR proteins will 
be reviewed and discussed.  
Factor H can bind to the surface of various cells through three major mechanisms: 
(1) First, as described in section 2.1., factor H binds on host surfaces to acceptor molecules, such 
as GAGs and sialic acid, which allow attachment of this regulator in order to protect the cells 
from complement attack. Other examples include host ligands exposed under specific conditions, 
such as malondialdehyde epitopes due to oxidative modification; DNA, annexin II and histones 
on apoptotic and necrotic cells [53, 54]; and binding to ECM proteins. 
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(2) Second, factor H may also bind to host surfaces through soluble host ligands, as exemplified 
by the recruitment of factor H to apoptotic cells by the pentraxins PTX3 and CRP [33, 35].  
(3) Third, factor H can bind to various cells through receptors. Receptor-bound factor H could 
still act as cofactor for factor I and aid in cellular protection against complement attack [55]. In 
addition, receptor-bound factor H can mediate or regulate cellular adhesion and activation, i.e. 
exert a function not related to its complement-regulatory capacity, as discussed below. Of note, 
the interaction of factor H with cells is often complex, as described for example for its interaction 
with platelets, involving both direct interaction with sialic acid, binding mediated by 
thrombospondin-1 and binding to the GPIIb/IIIa (αIIbβ3 integrin) receptor [56-58]. 
 
3.1. CR3 and CR4, the major factor H receptors 
Binding of factor H to several cell types is mediated by the complement receptors CR3 
(CD11b/CD18) and CR4 (CD11c/CD18) [55, 59-64]. In addition to factor H, these receptors bind 
a wide variety of other ligands, such as iC3b (the inactivated fragment of C3) fibrinogen, ICAM-
1, factor X, LPS etc. [65-68]. CR3 and CR4 belong to the family of beta2 integrins and are 
expressed mainly by myeloid cell types (monocytes, macrophages, dendritic cells, neutrophil 
granulocytes) in humans. They mediate several functions including cell-cell and cell-ECM 
contacts, proliferation, phagocytosis and transendothelial migration of immune cells [69-71]. 
Most important of them is the iC3b-mediated phagocytosis that is a crucial step in the elimination 
of complement-opsonized pathogens and apoptotic cells [72-75].  
 
3.2. Factor H binding to monocytes, macrophages and dendritic cells 
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Monocytes, macrophages and dendritic cells are essential innate immune cells involved in the 
initiation and resolution of inflammation, phagocytosis and killing of pathogens, antigen 
presentation, and instruction of the adaptive immune response. 
Early studies described functional effects of factor H on monocytes, without identifying 
the receptor, such as chemotactic effect [76, 77], stimulation of respiratory burst [78] and 
induction of IL-1β secretion [79]. Factor H was also shown to stimulate release of thromboxane 
and prostaglandin E from guinea pig peritoneal macrophages [80]. Direct interaction of factor H 
and myeloid cells has recently been studied by several groups in more detail. In a murine model 
of AMD, factor H was found to inhibit the resolution of inflammation by restraining the 
macrophages at the site of inflammation. This effect was mediated by factor H binding to CR3 on 
the surface of mononuclear phagocytes, which interaction blocked thrombospondin-1–CD47 
signaling that otherwise promotes the elimination of the phagocytes [81]. The immune 
modulating effect of two factor H variants were also analyzed in the context of AMD. The factor 
H H402 isoform was found to be more potent in inducing phagocyte accumulation compared to 
the more common (protective) variant Y402 [81]. In addition, in AMD patients elevated plasma 
levels of factor H bearing nitrated tyrosines was detected. Purified nitrated factor H showed 
impaired GAG and C3b binding, loss of cofactor activity, and induced inflammatory IL-8 
production in monocytes that had been stimulated with peroxidated lipids [82]. 
 In the context of apoptotic cell clearance, complement plays a major role and 
factor H seems to play important roles as well [83-85]. The presence of factor H on apoptotic 
cells under physiological and pathological conditions was demonstrated, and shown to be 
involved in the regulation of complement activation on dead cells [33, 53, 54, 60, 83]. Early 
apoptotic cells were found to bind and internalize soluble factor H and use it to increase iC3b 
deposition on their surface and to enhance their uptake by monocytes [86]. In contrast to this, in 
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the study of Kang et al., enhanced uptake of the factor H-coated apoptotic material was not 
observed despite its binding to CR3 on monocytes [60]. In the study of Martin et al., factor H-
coated apoptotic cells and nucleosomes induced, via Siglec-9, elevated production of the anti-
inflammatory cytokine IL-10 in monocytes; however, the possible role of CR3 in binding factor 
H and inducing tolerance was not investigated [86]. In addition, the modified (monomeric) form 
of CRP was shown to recruit factor H to apoptotic cells and particles and promote their uptake by 
macrophages in an anti-inflammatory manner [33, 83]. The induction of anti-inflammatory 
cytokine production upon binding of factor H-coated apoptotic cells to CR3 is in good agreement 
with studies showing that iC3b-coated apoptotic cells induce tolerance via CR3 signaling [87-90]. 
These studies indicate that factor H has an important role in the silent removal of 
apoptotic material by enhancing iC3b deposition and inducing tolerogenic signals. How factor H 
and iC3b – both deposited on the surface of dying cells and both ligands of CR3 – interact in this 
process needs further investigation; moreover, the role of CR4 needs to be addressed, as well. 
 The anti-inflammatory effect of cell bound factor H was also demonstrated for dendritic 
cells. Monocyte-derived dendritic cells (MDCs) differentiated in the presence of factor H did not 
respond to LPS stimulation with the well known activation markers, such as costimulatory 
receptor upregulation and pro-inflammatory cytokine production; rather they secreted IL-10 [91]. 
The authors concluded that factor H has to act on monocytes to induce these changes in MDC 
behavior, however, this is not achieved by factor H binding to CR3 or CR4 on monocytes [91].  
  
 
3.3. Factor H and neutrophil granulocytes 
Neutrophil granulocytes are rapidly recruited to infected tissue and have several killing 
mechanism to eliminate pathogens, thus they provide a first line of host cellular defense, and are 
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involved in a variety of pathophysiological processes [92-94]. Factor H binding to neutrophils 
was demonstrated by Avery and Gordon in 1993, which binding was found to be specific and 
could be enhanced by neutrophil activation [95]. This receptor-mediated binding was confirmed 
by other groups and the β2 integrin CR3 was identified as the major factor H receptor [55, 59, 
63]. While factor H can bind to CR4, as well, it is difficult to dissect CR3- and CR4-specific 
factor H effects on neutrophils because these cells express little amount of CR4. Upon binding to 
CR3, factor H retains its cofactor activity [55]. Because factor H could serve as an adhesion 
ligand for neutrophils [59] it is expected to affect several functions of neutrophil granulocytes, as 
migration, phagocytosis, degranulation and oxidant generation are all influenced by adhesion. 
Indeed, immobilized factor H could trigger calcium signal and spreading in adhered neutrophils 
[55]. DiScipio et al. [59] found that generation of hydrogen peroxide by neutrophils stimulated 
with C5a or TNFα was enhanced by factor H; lactoferrin release was also enhanced by adherence 
to factor H and stimulation by TNFα. Soluble factor H did not inhibit the adhesion of neutrophils 
to immobilized factor H [59]. In addition, factor H itself was shown to support neutrophil 
migration [55]. Immobilized factor H significantly enhanced the release of IL-8, a known 
migratory chemokine, by neutrophils, while for soluble factor H a similar effect was not 
observed. In contrast, the generation of reactive oxygen species (ROS) and the release of 
neutrophil extracellular traps (NETs) by neutrophils stimulated with phorbol 12-myristate 13-
acetate (PMA) or with immobilized fibronectin plus β-glucan were inhibited by immobilized 
factor H [55]. NETs can trap microorganism that are too large to be phagocytosed, and also play 
a direct role in killing pathogens [92, 94, 96]. Thus, factor H present in the body fluids appears 
not to stimulate neutrophils, only when deposited on a pathogen surface or in a tissue; it may 
affect the recruitment and activation of these inflammatory cells. On the other hand, factor H 
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could reduce host damage caused by an inflammatory environment through the inhibition of NET 
and ROS production. 
 
3.4. Factor H family proteins in the interaction of phagocytes with pathogens 
Complement factor H can also influence the immune response by modulating the interaction of 
phagocytes with pathogens (reviewed in [97]). Several microbes were shown to be able to bind 
factor H, e.g. Pseudomonas aeruginosa, Borrelia burgdorferi, Francisella tularensis, Candida 
albicans, Neisseria meningitidis, etc. [97-102]. On one hand, pathogens can avoid complement 
attack and opsonophagocytosis by recruiting factor H on their surface [97, 103-107]. On the other 
hand, factor H can enhance adhesion of the pathogen to phagocytes by binding to specific 
receptors [62, 63]. 
Candida albicans-bound factor H was shown to enhance the binding of the yeast to 
neutrophil granulocytes, and to enhance neutrophil migration, ROS production, phagocytosis and 
fungal killing [63]. These effects were mediated via factor H binding to CR3 on neutrophils. 
FHL-1, FHR-1 and FHR-4A were also shown to bind to neutrophils; FHL-1 and FHR-1 bind via 
CR3, whereas the FHR-4A receptor is distinct from CR3. Similar to factor H, FHR-1 when 
bound to C. albicans, supported neutrophil migration, enhanced adhesion, phagocytosis and 
antimicrobial activities, such as lactoferrin release, ROS production and fungal killing. Although 
FHL-1 could also enhance neutrophil adhesion to yeast cells, it had no measurable effect on 
migration and did not affect the antimicrobial activities under the given experimental conditions. 
For FHR-4A, no such functional activities were found [63]. 
Factor H-opsonized C. albicans acted similarly on macrophages, namely, factor H 
enhanced the production of the pro-inflammatory cytokines IL-1β and IL-6 by macrophages 
exposed to yeasts [64]. However, this pathogen can release a protease that – among others – 
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cleaves and inactivates factor H and its receptors on macrophages [64]. The pro-inflammatory 
cytokine production of macrophages was elevated also by stimulation with factor H-coated 
Mycobacterium bovis compared to stimulation with the bacteria only, although factor H inhibited 
the uptake of the bacteria by the cells [108]. 
Recently, extracellular DNA trap formation in the case of monocytes (MoETs) when 
exposed to C. albicans was demonstrated and, like NETs, these MoETs were shown to activate 
complement and bear factor H bound to the extracellular DNA [109]. While deposited factor H in 
neutrophils induced IL-8 production, MoET-associated factor H had an anti-inflammatory action 
on monocytes by blocking their IL-1β production [55, 109]. Thus, it is possible that by 
interacting with surface-bound factor H, neutrophils can alert and recruit other cells to the site of 
infection or inflammation through secretion of the chemotactic cytokine IL-8, while monocytes 
take control over the extent of inflammation. 
In summary, while some pathogens can exploit host factor H to their benefit in order to 
down-regulate opsonization, factor H can promote interaction between phagocytes and pathogens 
in a direct receptor-mediated manner. Since complement activation is a rapid process, and bound 
factor H can effectively reduce the amount of deposited C3b and C3b-derived opsonins on the 
pathogen surface, it is likely that microbial complement evasion is particularly relevant in body 
fluids where complement is abundant and the microbes can more easily disseminate. The role of 
factor H in modulating phagocyte responses in the context of infection is more likely to be 
relevant in the tissues. In this way, factor H can protect the host not only by limiting complement-
mediated damage, but also by mediating cellular responses, including the regulation of the 
inflammatory microenvironment and the elimination of the pathogens. Further studies will also 
be needed to investigate whether and how other pattern-recognition receptors, particularly Toll-
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like receptors expressed on the phagocytes take part in these processes and influence the effect of 
factor H bound on the microbes. 
 
3.5. Factor H, FHR-3 and B cells 
Factor H was shown to bind to B lymphocytes, but the factor H receptor(s) could not be 
identified at the molecular level [110-112]. Factor H was shown to induce complement factor I 
release from the B cells [113], block immunoglobulin secretion  [114], as well as support their 
proliferation [115]. These early studies, however, were not followed upon, thus a direct B cell 
activation modulating role of factor H remains uncertain. 
 An indirect role of modulating B cell activation was recently shown for FHR-3. Like 
other FHR proteins, FHR-3 can bind to certain fragments of C3b. In their study, Buhlmann et al. 
demonstrated that FHR-3 can block the activation of B cells by inhibiting C3d binding to the B-
cell co-receptor CR2, whereas factor H and FHR-1 showed no such effect [116]. 
 While data regarding the interaction and modulatory function of factor H family proteins 
on B cells are scarce, such mechanisms may provide a further link between innate and adaptive 
immunity, and may prove relevant in disease settings, such as certain autoimmune disorders. For 
example, the deletion of the CFHR1 gene has been found to predispose to the autoimmune form 
of atypical hemolytic uremic syndrome, which is associated with the appearance of pathogenic 
autoantibodies against factor H, possibly due to lack of induction of tolerance against FHR-1 
[117]. Similarly, the loss of the FHR-3 and FHR-1 proteins due to deletion of the CFHR3 and 
CFHR1 genes predisposes to systemic lupus erythematosus [118]. Further studies are needed to 
clarify the role of these proteins in developing autoantibodies and study the possibility of their 
direct effects on B cells. 
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3.6. Other cell types 
Factor H and FHL-1 were shown to interact also with some non-immune cells via specific 
receptors. The binding of factor H to CR3 was shown to promote the adherence of Streptococcus 
pneumoniae to epithelial cells and facilitate the uptake of pneumococci by these cells (also by 
neutrophils) [62]. In an in vitro model, factor H also facilitated the adherence of Neisseria 
gonorrhoeae to CHO cells transfected with CR3; however, FHL-1 and FHR-1 could not bridge 
gonococci with the CR3-CHO cells [61]. FHL-1 was demonstrated to support spreading and 
attachment of three anchorage-dependent cells lines, CCL-64 mink lung epithelial-like cells, C32 
human melanoma cells, and MRC-5 human fibroblast-like cells, presumably via integrin 
receptors [119]. 
 Thus, factor H and other factor H family proteins may bind to and modulate the activity of 
non-immune cells, as well. Additional factor H receptors, such as L-selectin [120], were also 
proposed, which need to be further investigated in the future. 
  
4. Conclusion 
By regulating and modulating complement activation, factor H, FHL-1 and the FHR proteins 
influence opsonization and opsonophagocytosis of host and nonhost particles and cells [30, 44, 
97]. In their additional role, these proteins bind to cellular receptors and regulate cell activation 
and inflammation. Apparently, depending on the context, e.g. the nature of additional stimuli like 
pathogens, factor H can exert both pro- and anti-inflammatory activities on immune cells. Recent 
exciting studies signal a renewed interest in such cellular effects of particularly factor H. Future 
studies are expected to advance our understanding of the mechanisms of receptor-mediated 
cellular functions of the factor H family proteins and answer the question, to what extent this 
non-canonical role of factor H or the FHRs contribute to diseases, such as it was suggested for 
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AMD. This knowledge may be applied in the future to manipulate these proteins or their 
receptor/ligand interactions in a therapeutically useful way. 
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Figure legends 
Fig. 1. The role of factor H family proteins in complement regulation. 
The complement system can be activated via three major pathways, the classical, lectin and 
alternative pathways. These activation pathways merge upon the cleavage of C3 into the 
anaphylatoxin C3a and opsonin C3b by the C3 convertase enzymes of the classical/lectin 
pathways (C4b2b) and the alternative pathway (C3bBb). The generated C3b can feed back to the 
alternative pathway via the so-called amplification loop by forming additional C3bBb 
convertases. By binding to the C3 convertases, C3b also allows formation of the C5 convertase 
enzymes that generate from C5 the anaphylatoxin C5a, and the C5b fragment, which can initiate 
the terminal pathway and ultimately form the lytic C5b-9 complex. Factor H and FHL-1 act as 
cofactors for factor I for the enzymatic inactivation of C3b, and also inhibit the alternative 
pathway C3 convertase and the C5 convertases. In contrast to this negative regulatory role, the 
FHR proteins FHR-1, FHR-4 and FHR-5 enhance complement activation by competitive 
inhibition of factor H and/or enhance the formation of the C3bBb convertase by binding C3b. 
 
Fig. 2. Schematic overview of the factor H family proteins. 
Factor H is composed of 20 complement control protein (CCP) domains, of which the N-terminal 
4 CCPs mediate the complement inhibiting activity of the protein. Factor H-like 1 (FHL-1) is 
identical with the CCPs 1-7 of factor H, plus has four unique amino acids at its C-terminus. The 
major ligand binding sites are indicated with horizontal lines below the corresponding domains of 
factor H/FHL-1. The factor H-related FHR proteins are composed of 4 to 9 CCP domains, 
displaying varying degrees of amino acid sequence identity to certain factor H domains (indicated 
by vertical alignment; identical colors indicate complete or very high degree of sequence 
identity). The CCPs 1-2 of FHR-1, FHR-2 and FHR-5 (shown in green) are closely related to 
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each other and mediate dimerization of these FHRs. Due to the conservation of domains 
homologous to factor H CCPs 6-9 and 18-20 among the FHRs, FHRs can bind some of the 
ligands of factor H, thus factor H and the FHRs have partly overlapping ligand binding profiles. 
GAGs, glycosaminoglycans; MDA, malondialdehyde; CRP, C-reactive protein; PTX3, pentraxin 
3; CR, complement receptor. 
 
Fig. 3. Interactions of factor H family proteins. 
(A) Factor H, by binding to its main complement ligand C3b, inhibits complement activation. 
This activity is exploited by tumour cells and certain microbes via sequestering factor H. Factor 
H also interacts with a number of host ligands that allow targeting of the complement inhibitory 
activity to inflammatory sites and certain cellular (e.g, platelets, endothelial cells, apoptotic and 
necrotic cells) and non-cellular (ECM and basement membranes) surfaces. The FHR proteins 
may directly activate complement by binding C3b and allowing formation of the alternative 
pathway C3 convertase C3bBb (FHR-1, FHR-4, FHR-5) and also compete with factor H for 
binding to deposited C3b and selected ligands, such as pentraxins and ECM. FHR-3 was shown 
to inhibit factor H binding to Neisseria meningitidis. Thus, the balance between complement 
activation and inhibition is shifted towards inhibition by factor H and towards activation by 
FHRs. Future studies will clarify the exact ligand binding profiles, factor H-inhibiting capacity 
and functional overlaps/redundancy of the FHR proteins, as well as the role of FHRs in 
complement evasion of tumour cells and microbes. Note that not all reported factor H ligands are 
included in the figure; for a more comprehensive overview see e.g. [10, 11, 121]. ECM, 
extracellular matrix; GAGs, glycosaminoglycans; MDA, malondialdehyde; CRP, C-reactive 
protein; PTX3, pentraxin 3; 
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(B) Schematic overview of the current knowledge of the interaction of factor H family proteins 
with immune cells and the receptors mediating binding of these proteins. Note that GAG/sialic 
acid-mediated binding of factor H to cells is not shown, only interactions with cellular receptors. 
Factor H may bind through receptors to other cell types, such as epithelial cells, as well. CR4 is 
weakly expressed on neutrophils (shown in grey). CR, complement receptor. 
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Table 1. Summary of the cellular roles of factor H family proteins 
Factor H family 
protein 
Cell type Receptor Effect Reference 
Factor H Neutrophil 
granulocyte 
CR3 Enhanced 
adhesion, 
lactoferrin- and 
hydrogen 
peroxide 
production 
[59] 
 Neutrophil 
granulocyte 
CR3, CR4# Enhancement of 
adhesion to C. 
albicans, 
increased 
migration, 
lactoferrin and 
ROS production, 
and fungal killing 
[63] 
 Neutrophil 
granulocyte 
CR3 Enhanced 
adhesion and 
uptake of 
pneumococci 
[62] 
 Neutrophil 
granulocyte 
CR3 Enhancement of 
migration, 
spreading, IL-8 
release; 
Inhibition of 
NET formation 
[55] 
 Monocyte ? Chemotactic 
effect; induction 
of respiratory 
burst and IL-1β 
secretion 
[76-79] 
 Monocyte CR3, Siglec-9 Migration, 
Antiinflammatory 
effect (IL-10) 
[86, 91, 109] 
 Macrophage CR3, CR4 Accumulation at 
inflammatory 
site* 
[81] 
 Macrophage CR3, CR4 Proinflammatory 
cytokine 
production in the 
context of 
pathogen 
[64, 108] 
 B cells ? Stimulation of 
proliferation* and 
factor I release, 
[113-115] 
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inhibition of 
immunoglobulin 
secretion 
 Epithelial cells CR3 Enhanced 
adhesion and 
uptake of 
pneumococci 
[62] 
 Platelets GPIIb/IIIa ? (possibly 
complement 
inhibition) 
[58] 
FHL-1 Epithelial-, 
melanoma and 
fibroblast cell 
lines 
? Spreading, 
attachment 
[119] 
 Neutrophil 
granulocyte 
CR3, CR4# Adhesion [63] 
FHR-1 Neutrophil 
granulocyte 
CR3 Enhancement of 
adhesion to C. 
albicans, 
increased 
migration, 
lactoferrin and 
ROS production, 
and fungal killing  
[63] 
FHR-3 B cell (FHR-3 binds to 
the CR2-ligand 
C3d) 
FHR-3, by 
binding C3d, 
blocks co-
activation of the 
cells 
[116] 
* Described for murine cells 
# CR4 is weakly expressed on neutrophils. 
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